EH-EU13 - Tuesday case mailing - #1 - test

There was an error on your page. Please correct any required fields and submit again. Go to the first error
Thank You!

Weekly case #01


View case
You answered: A
A) Cabazitaxel     B) AR-pathway inhibitor

The most appropriate option according to the Mirrors of Medicine expert panel:

B
The panel of experts considered an AR-pathway inhibitor (abiraterone or enzalutamide) to be an appropriate option for patients with primary or secondary progression after docetaxel treatment.
View evidence & guidelines
behind this consideration

 

This patient case is related to the Mirrors of Medicine model on 'Metastatic castration-resistant prostate cancer'